Compare VCEL & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCEL | EFC |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | 400 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1996 | N/A |
| Metric | VCEL | EFC |
|---|---|---|
| Price | $32.58 | $11.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $58.50 | $14.55 |
| AVG Volume (30 Days) | 468.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.22% |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $17.96 | $52.40 |
| P/E Ratio | $101.67 | ★ $9.50 |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $29.24 | $11.12 |
| 52 Week High | $48.75 | $14.12 |
| Indicator | VCEL | EFC |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 34.11 |
| Support Level | $31.34 | $11.57 |
| Resistance Level | $38.48 | $14.00 |
| Average True Range (ATR) | 1.42 | 0.27 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 20.52 | 34.36 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.